Terms: = Endocrine gland cancer AND SUFU, RP11-47A8_1, 51684, ENSG00000121410, PRO1280, SUFUXL, Q9UMX1, SUFUH AND Prognosis
10273 results:
1. Dual‑regulated oncolytic adenovirus carrying
Zhao T; Ye W; Zhang R; Zhu X; Shi Q; Xu X; Chen W; Xu L; Meng Y
Mol Med Rep; 2024 Jul; 30(1):. PubMed ID: 38757346
[TBL] [Abstract] [Full Text] [Related]
2. A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classification.
Woo CS; Ho RS; Ho G; Lau HT; Fong CH; Chang JY; Leung EK; Tang LC; Ma IK; Lee AC; Lui DT; Woo YC; Chow WS; Leung GK; Tan KC; Lam KS; Lee CH
Front Endocrinol (Lausanne); 2024; 15():1368944. PubMed ID: 38756997
[TBL] [Abstract] [Full Text] [Related]
3. CircAGFG1 Promotes Ovarian cancer Progression Through the miR-409-3 p/ZEB1 Axis.
Luo J; Zhong H; Guo M; Xiao P; Cao R; Zhao M; Jing Y
Technol Cancer Res Treat; 2024; 23():15330338241252423. PubMed ID: 38752261
[TBL] [Abstract] [Full Text] [Related]
4. EMP1 correlated with cancer progression and immune characteristics in pan-cancer and ovarian cancer.
Zhang J; Yang J; Li X; Mao L; Zhang Y; Liu Y; Bao Y
Mol Genet Genomics; 2024 May; 299(1):51. PubMed ID: 38743077
[TBL] [Abstract] [Full Text] [Related]
5. [The clinicopathological features of adult thyroid tumors with DICER1 mutation].
Tang J; Huang JJ; Luo YL; Zhang LK; Wang QQ; Chen J; Liu ZY
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1623-1627. PubMed ID: 38742350
[TBL] [Abstract] [Full Text] [Related]
6. WHO 2022 updates on follicular cell and c-cell derived thyroid neoplasm.
Goswami P; Patel T; Dave R; Singh G; Singh A; Kalonia T
J Med Life; 2024 Jan; 17(1):15-23. PubMed ID: 38737660
[TBL] [Abstract] [Full Text] [Related]
7. Columnar Cell Thyroid Carcinoma: A Heterogeneous Entity Demonstrating Overlap Between Papillary Thyroid Carcinoma and Follicular Neoplasms.
Higgins KE; Sadow PM; Johnson DN; Wang P; Wanjari P; Cipriani NA
Head Neck Pathol; 2024 May; 18(1):39. PubMed ID: 38727854
[TBL] [Abstract] [Full Text] [Related]
8. A Competing Risk Nomogram for Prediction of prognosis in Patients With Primary Squamous Cell Thyroid Carcinoma.
Tian Y; He L; Zhang B; Deng L; Wang J
Technol Cancer Res Treat; 2024; 23():15330338241254059. PubMed ID: 38725285
[No Abstract] [Full Text] [Related]
9. Prognostic value of postoperative anti-thyroglobulin antibody in patients with differentiated thyroid cancer.
Zhao Y; Mu Z; Liang D; Zhang T; Zhang X; Sun D; Sun Y; Liang J; Lin Y
Front Endocrinol (Lausanne); 2024; 15():1354426. PubMed ID: 38721144
[TBL] [Abstract] [Full Text] [Related]
10. [Analysis of factors affecting the prognosis of patients with pancreatic cancer patients with obstructive jaundice].
Zhang L; Li M; Sun QF; Yu HP
Zhonghua Nei Ke Za Zhi; 2024 May; 63(5):474-479. PubMed ID: 38715484
[No Abstract] [Full Text] [Related]
11. Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells.
Zhong P; Nakata K; Oyama K; Higashijima N; Sagara A; Date S; Luo H; Hayashi M; Kubo A; Wu C; He S; Yamamoto T; Koikawa K; Iwamoto C; Abe T; Ikenaga N; Ohuchida K; Morisaki T; Oda Y; Kuba K; Nakamura M
J Exp Clin Cancer Res; 2024 May; 43(1):138. PubMed ID: 38715057
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic significance of preoperative lymphocytes, albumin, and neutrophils (LANR) index in resectable pancreatic ductal adenocarcinoma.
Zhuang J; Wang S; Wang Y; Wu Y; Hu R
BMC Cancer; 2024 May; 24(1):568. PubMed ID: 38714979
[TBL] [Abstract] [Full Text] [Related]
13. Treatment strategies for borderline resectable pancreatic neuroendocrine tumors: a narrative review.
Chang JY; Ruff SM; Cloyd JM
Chin Clin Oncol; 2024 Apr; 13(2):25. PubMed ID: 38711178
[TBL] [Abstract] [Full Text] [Related]
14. Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study.
Poiraud C; Lenne X; Bruandet A; Theis D; Bertrand N; Turpin A; Truant S; El Amrani M
World J Surg Oncol; 2024 May; 22(1):123. PubMed ID: 38711136
[TBL] [Abstract] [Full Text] [Related]
15. Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma.
Guo F; Fu G; Li F; Hua Y; Wang Z; Zheng X; Zhao J; Gao M
World J Surg Oncol; 2024 May; 22(1):121. PubMed ID: 38711029
[TBL] [Abstract] [Full Text] [Related]
16. piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in Ovarian cancer.
Yan Y; Tian D; Zhao B; Li Z; Huang Z; Li K; Chen X; Zhou L; Feng Y; Yang Z
Technol Cancer Res Treat; 2024; 23():15330338241249692. PubMed ID: 38706262
[TBL] [Abstract] [Full Text] [Related]
17. Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.
Zhang Q; Zhong ZZ; Wu T; He YQ
BMC Surg; 2024 May; 24(1):133. PubMed ID: 38702652
[TBL] [Abstract] [Full Text] [Related]
18. Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer.
Ren J; Wu S; Su T; Ding J; Chen F; Li J; Wang Z; Han L; Wu Z
Cancer Med; 2024 May; 13(9):e7229. PubMed ID: 38698688
[TBL] [Abstract] [Full Text] [Related]
19. Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer.
Wang Y; Chen X; Chen Q; Liu T; Wu Y; Huang L; Chen Y
J Cell Mol Med; 2024 May; 28(9):e18371. PubMed ID: 38686496
[TBL] [Abstract] [Full Text] [Related]
20. Targeting KRAS in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract] [Full Text] [Related]
[Next]